Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02792218 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 930
- Enrollment target
NCT02792218: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT02792218 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 930 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02792218, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 930 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
Primary Outcome
ARR was the number of confirmed relapses in a year, calculated as the total number of relapses for all participants in the treatment group divided by the total participant-years of time in study. A confirmed MS relapse was defined as one accompanied by a clinically-relevant change in the EDSS performed by the Independent EDSS rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores or 2 points on one functional score (excluding changes
Interventions
- DRUG Ofatumumab subcutaneous injection
- DRUG Teriflunomide-matching placebo capsules
- DRUG Teriflunomide capsule
- DRUG Matching placebo of ofatumumab subcutaneous injections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 930 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 3 |
What the finished NCT02792218 record still lists
NCT02792218 is an interventional study that assigns participants to a tested intervention. The registered 930 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 4 interventions - of which Ofatumumab subcutaneous injection is the first listed.
NCT02792218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02792218 about?
NCT02792218 is a clinical study titled "Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis". To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
What is the current status of trial NCT02792218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 930 participants. The study started on 2016-09-20. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT02792218?
The interventions under investigation include: Ofatumumab subcutaneous injection (DRUG), Teriflunomide-matching placebo capsules (DRUG), Teriflunomide capsule (DRUG), Matching placebo of ofatumumab subcutaneous injections (DRUG).
Who is sponsoring clinical trial NCT02792218?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02792218's enrollment target sits among peer trials
930 338th of 2000 higher than 1,662 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI